Safety, Pharmacokinetics, and Antiretroviral Activity of the Potent, Specific Human Immunodeficiency Virus Protease Inhibitor Nelfinavir: Results of a Phase I/II Trial and Extended Follow-up in Patients Infected with Human Immunodeficiency Virus-Reference-Cited by-同舟云学术

Safety, Pharmacokinetics, and Antiretroviral Activity of the Potent, Specific Human Immunodeficiency Virus Protease Inhibitor Nelfinavir: Results of a Phase I/II Trial and Extended Follow-up in Patients Infected with Human Immunodeficiency Virus

Published:1998-08 Issue:8 Volume:38 Page:736-743
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:

Author:

Moyle Graeme J.,Youle Michael,Higgs Chris,Monaghan Jo,Prince William,Chapman Sharon,Clendeninn Neil,Nelson Mark R.

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference19 articles.

1. Safety and activity of saquinavir in HIV infection;Kitchen;Lancet,1995

2. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease;Danner;New Engl J Med,1995

3. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection;Markowitz;New Engl J Med,1995

4. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir;Kelleher;J Infect Dis,1996

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nelfinavir inhibition of Kaposi’s sarcoma-associated herpesvirus protein expression and capsid assembly;Infectious Agents and Cancer;2024-03-04

2. Nelfinavir Inhibition of Kaposi’s sarcoma-associated herpesvirus protein expression and capsid assembly;2023-11-08

3. Drug repurposing screens identify chemical entities for the development of COVID-19 interventions;Nature Communications;2021-06-03

4. The FDA-Approved Drug Nelfinavir Inhibits Lytic Cell-Free but Not Cell-Associated Nonlytic Transmission of Human Adenovirus;Antimicrobial Agents and Chemotherapy;2020-08-20

5. Oral drug repositioning candidates and synergistic remdesivir combinations for the prophylaxis and treatment of COVID-19;2020-06-16